Table 3 Emerging strategies of enhanced SDT for BC and PCa
From: Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges
Sonosensitizers | Biological model | Strategy | Result | Refs. |
|---|---|---|---|---|
AMVs | Subcutaneous patient-derived bladder tumor tissue sample in nude mice | Combination of AIE-active sonosensitizer and patient-derived MVs | The superior tumor targeting ability and efficient personalized SDT therapy on PDX models | [81] |
CAT-TCPP/FCS NPs | Orthotopic MB49 in C57BL/6 mice | CAT loading to alleviate tumor hypoxia; FCS as an effective transmucosal delivery carrier | Orthotopic bladder tumors under US without systemic toxicity | [71] |
MVSN-IR825 | Subcutaneous and orthotopic PC-3 in nude mice | Combination of virus‐mimic surface topology and MB‐assisted LFUS; Combination of PAI, FI, and MRI; combination with PDT and PTT | A successful combined anticancer effect with trimodal imaging to determine the optimal therapeutic timing | [82] |
CS-ss-IR806 (CSR) | Subcutaneous PC-3 in nude mice | Redox- and hyaluronidase-responsive drug delivery; combination with PDT and PTT | Superior trimodal anticancer efficacy after dual-irradiation compared with either monoirradiation strategy | [80] |
HPNPs | Subcutaneous LNCaP in nude mice | pH- and cathepsin B- responsive drug delivery | SDT-mediated tumor elimination with no adverse effects | [79] |
HHSN-C/P-mAb | Subcutaneous PC-3 in nude mice | PSCA monoclonal antibody conjugation; pH-responsiveness; combination of US imaging and MRI; combination with chemotherapy | High-effective synergistic therapy | [164] |
TiO2: Gd@DOX/FA | Subcutaneous LNCaP in nude mice | pH-responsive drug delivery; MRI; combination with chemotherapy | Smaller tumor sizes of all the nanomedicine groups than free dox (v:v0 = 4.2) | [162] |